Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Surg. Nov 27, 2026; 18(11): 122614
Published online Nov 27, 2026. doi: 10.4240/wjgs.122614
Published online Nov 27, 2026. doi: 10.4240/wjgs.122614
Omeprazole-cisapride combination for gastroparesis following radical gastrectomy for gastric cancer: An efficacy and safety analysis
Shan-Ling Zhu, Qian Gao, Yang Liu, Kun-Peng Cheng, Department of Gastroenterology Medi
Author contributions: Zhu SL performed the study; Zhu SL, Gao Q, and Liu Y analyzed the data; Cheng KP designed the research and wrote the manuscript. All authors have read and approve the final manuscript.
AI contribution statement: No AI tools were used in the preparation of this manuscript.
Institutional review board statement: Given the retrospective design and data anonymization, approval from the ethics review committee is waived.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Corresponding author: Kun-Peng Cheng, Associate Chief Physician, Department of Gastro
Received: June 10, 2026
Revised: July 16, 2026
Accepted: August 26, 2026
Published online: November 27, 2026
Processing time: 154 Days and 19 Hours
Revised: July 16, 2026
Accepted: August 26, 2026
Published online: November 27, 2026
Processing time: 154 Days and 19 Hours
Core Tip
Core Tip: This retrospective study evaluated the clinical efficacy and safety of omeprazole (OME) combined with cisapride in patients with gastroparesis following radical gastrectomy for gastric cancer. The combination regimen was more effective than OME alone without increasing the overall incidence of adverse reactions. It also demonstrated clinical advantages in promoting symptom relief, accelerating gastrointestinal function recovery, and actively regulating gastrointestinal hormones. Patients with stage IIB-III disease, baseline motilin < 309 mg/L, and treatment with OME alone were at increased risk of treatment inefficacy.